文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性去势抵抗性前列腺癌患者中177Lu-rhPSMA-10.1与177Lu-PSMA-I&T的个体内剂量学比较

An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2023-12-01

在4例晚期转移性去势抵抗性前列腺癌患者中,于治疗前分别给予1.06±0.05 GBq的177Lu-rhPSMA-10.1和1.09±0.02 GBq的177Lu-PSMA-I&T进行个体内剂量学比较。结果显示177Lu-rhPSMA-10.1的肾脏吸收剂量更高(0.68±0.30 vs 0.46±0.10 mGy/MBq),但肿瘤病灶吸收剂量平均高3.3倍(范围1.2-8.3倍),治疗指数在所有患者中高1.1-3.1倍。

要点

  • 177Lu-rhPSMA-10.1的肾脏吸收剂量为0.68±0.30 mGy/MBq,高于177Lu-PSMA-I&T的0.46±0.10 mGy/MBq。
  • 177Lu-rhPSMA-10.1对单个肿瘤病灶的吸收剂量平均为177Lu-PSMA-I&T的3.3倍(范围1.2-8.3倍)。
  • 所有患者中177Lu-rhPSMA-10.1的治疗指数为177Lu-PSMA-I&T的1.1-3.1倍。

核心结论

  • 与177Lu-PSMA-I&T相比,使用177Lu-rhPSMA-10.1可显著提高肿瘤吸收剂量并改善治疗指数。
  • 改善的治疗指数提供了灵活性:可在预设肾脏剂量限值内最大化肿瘤吸收剂量,或在早期疾病中降低肾脏辐射暴露同时仍达到有效肿瘤剂量。
  • 肾脏等高危器官的功能正在一项前瞻性临床试验中评估。

研究设计与样本

  • 研究纳入4例连续的组织学证实的晚期转移性去势抵抗性前列腺癌患者,计划接受放射性配体治疗。
  • 每例患者在治疗前至少间隔7天分别接受1.06±0.05 GBq的177Lu-rhPSMA-10.1和1.09±0.02 GBq的177Lu-PSMA-I&T。
  • 剂量学评估采用全身平面闪烁显像(注射后5分钟、4小时、1天、2天和7天)及胸腹部SPECT/CT(注射后4小时、1天、2天和7天)。
  • 全身和唾液腺剂量基于全身平面显像计数评估;肾脏、肝脏、脾脏、骨髓和肿瘤病灶(每例患者≤4个)剂量基于SPECT/CT图像绘制的容积内活性评估。
  • 剂量采用OLINDA/EXM 1.0版计算,并计算每例患者的治疗指数(TI),即转移灶平均剂量与肾脏平均剂量之比。

主要发现

  • 177Lu-rhPSMA-10.1的肾脏吸收剂量为0.68±0.30 mGy/MBq,高于177Lu-PSMA-I&T的0.46±0.10 mGy/MBq。
  • 177Lu-rhPSMA-10.1对单个肿瘤病灶的吸收剂量平均为177Lu-PSMA-I&T的3.3倍(范围1.2-8.3倍)。
  • 个体内比较显示,所有评估患者中177Lu-rhPSMA-10.1的治疗指数为177Lu-PSMA-I&T的1.1-3.1倍。
  • 177Lu-rhPSMA-10.1的有效全身剂量为0.038±0.008 mSv/MBq,177Lu-PSMA-I&T为0.022±0.005 mSv/MBq。

关键数值与推荐

  • 177Lu-rhPSMA-10.1给药活度为1.06±0.05 GBq,177Lu-PSMA-I&T为1.09±0.02 GBq,两者至少间隔7天给药。
  • 肾脏吸收剂量:177Lu-rhPSMA-10.1为0.68±0.30 mGy/MBq,177Lu-PSMA-I&T为0.46±0.10 mGy/MBq。
  • 肿瘤病灶吸收剂量:177Lu-rhPSMA-10.1平均为177Lu-PSMA-I&T的3.3倍(范围1.2-8.3倍)。
  • 治疗指数:177Lu-rhPSMA-10.1为177Lu-PSMA-I&T的1.1-3.1倍。
  • 有效全身剂量:177Lu-rhPSMA-10.1为0.038±0.008 mSv/MBq,177Lu-PSMA-I&T为0.022±0.005 mSv/MBq。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the use of radioligand therapy moves earlier in the prostate cancer timeline, minimizing the absorbed dose to normal organs while maintaining high tumor radiation doses becomes more clinically important because of the longer life expectancy of patients. We performed an intrapatient comparison of pretherapeutic dosimetry with the novel radiohybrid prostate-specific membrane antigen-targeting radiopharmaceutical 177Lu-rhPSMA-10.1, along with 177Lu-PSMA-I&T, in patients with metastatic castration-resistant prostate cancer. Methods: Four consecutive patients with advanced histologically proven metastatic castration-resistant prostate cancer who were scheduled for radioligand therapy were evaluated. Before undergoing therapy, each patient received 1.06 ± 0.05 GBq of 177Lu-rhPSMA-10.1 and 1.09 ± 0.02 GBq of 177Lu-PSMA-I&T at least 7 d apart. For dosimetric assessment, whole-body planar scintigraphy was performed after 5 min, 4 h, 1 d, 2 d, and 7 d. In addition, SPECT/CT images were acquired over the thorax and the abdomen, 4 h, 1 d, 2 d, and 7 d after injection. Dosimetry of the whole body and salivary glands was based on the evaluation of the counts in whole-body planar imaging. Dosimetry of the kidneys, liver, spleen, bone marrow, and tumor lesions (≤4 per patient) was based on the activity in volumes drawn on SPECT/CT images. Doses were calculated using OLINDA/EXM version 1.0. The therapeutic index (TI), or ratio between mean dose of the metastases and mean dose of the kidneys, was calculated for each patient. Results: We found the dose to the kidneys to be higher with 177Lu-rhPSMA-10.1 than with 177Lu-PSMA-I&T (0.68 ± 0.30 vs. 0.46 ± 0.10 mGy/MBq); however, 177Lu-rhPSMA-10.1 delivered an average of a 3.3 times (range, 1.2-8.3 times) higher absorbed radiation dose to individual tumor lesions. Consequently, intraindividual comparison revealed a 1.1-3.1 times higher TI for 177Lu-rhPSMA-10.1 than for 177Lu-PSMA-I&T in all evaluated patients. The effective whole-body dose was 0.038 ± 0.008 mSv/MBq for 177Lu-rhPSMA-10.1 and 0.022 ± 0.005 mSv/MBq for 177Lu-PSMA-I&T. Conclusion: Using 177Lu-rhPSMA-10.1 can significantly increase the tumor-absorbed dose and improve the TI compared with 177Lu-PSMA-I&T. An improved TI gives the flexibility to maximize tumor-absorbed doses up to a predefined renal dose limit or, in earlier disease, to reduce the radiation exposure to the kidney while still achieving an effective tumor dose. The function of at-risk organs such as the kidneys is being assessed in a prospective clinical trial.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rinscheid A, Gäble A, Wienand G, et al. An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2023. PMID: 37770108. doi:10.2967/jnumed.123.265970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。